deliber
expos
human
infecti
agent
requir
enough
natur
acquir
infect
yield
suffici
subject
studi
despit
ubiqu
viral
cold
number
factor
make
studi
natur
acquir
infect
problemat
although
rv
commonest
etiolog
agent
viral
cold
sever
viral
caus
nonvir
caus
upper
airway
symptom
clinic
syndrom
caus
differ
viru
type
indistinguish
factor
contribut
variabl
natur
acquir
infect
includ
differ
rout
inocul
eye
nasopharynx
direct
contact
aerosol
etc
differ
inocul
dose
variabl
percept
symptom
lead
differ
time
present
host
factor
immun
statu
smoke
age
etc
influenc
viral
pathogen
heterogen
natur
natur
occur
infect
requir
larg
patient
number
need
identifi
statist
signific
effect
treatment
therefor
human
experiment
infect
studi
attract
proposit
allow
known
etiolog
agent
administ
standard
dose
rout
inocul
time
point
select
group
recipi
similar
characterist
eg
age
smoke
histori
healthdiseas
antibodi
statu
detail
follow
carri
control
clinic
set
sampl
collect
defin
time
point
relat
time
infect
clinic
syndrom
induc
rv
challeng
young
healthi
volunt
benign
selflimit
experiment
rv
infect
group
rel
uncontroversi
perhap
risk
subject
possibl
addit
infecti
agent
present
inoculum
good
manufactur
practic
gmp
prepar
stock
requir
regul
experiment
infect
studi
human
contraven
risk
studi
healthi
volunt
central
establish
key
aspect
biolog
rv
infect
includ
rout
acquisit
infect
clinic
symptom
inflammatori
immun
respons
involv
lower
airway
correl
immun
protect
rv
infect
viru
challeng
studi
also
use
healthi
volunt
evalu
vast
array
potenti
treatment
howev
none
studi
led
licens
singl
treatment
common
cold
licens
approv
sought
antivir
drug
pleconaril
treatment
rv
infect
approv
deni
food
drug
administr
advers
effect
outweigh
benefit
healthi
subject
selflimit
cold
lack
approv
antivir
treatment
cast
doubt
whether
continu
invest
viral
challeng
studi
justifi
howev
recognit
rv
infect
associ
sever
clinic
manifest
peopl
chronic
lung
diseas
asthma
copd
provid
new
impetu
research
new
direct
human
experiment
infect
studi
earli
prevail
view
rv
infect
result
selflimit
mild
upper
respiratori
tract
syndrom
occasion
report
rv
infect
associ
sever
clinic
ill
pneumonia
scientif
pharmacolog
research
tend
focus
respiratori
virus
influenza
respiratori
syncyti
viru
consid
seriou
human
pathogen
cold
long
associ
asthma
exacerb
earli
studi
investig
viru
infect
asthma
copd
exacerb
report
low
detect
rate
consensu
asthma
exacerb
predominantli
trigger
allergen
exposur
copd
exacerb
acut
bacteri
infect
develop
highli
sensit
specif
molecular
diagnost
techniqu
use
polymeras
chain
reaction
pcr
technolog
led
revolut
viral
diagnost
reevalu
role
respiratori
virus
rang
clinic
syndrom
particularli
pertin
human
rv
either
difficult
imposs
cultur
eg
rvc
strain
due
larg
number
serotyp
diagnost
serolog
test
feasibl
pcrbase
diagnost
test
much
greater
sensit
detect
rv
studi
use
pcr
reveal
rang
clinic
ill
associ
rv
infect
much
broader
previous
recogn
includ
sever
diseas
syndrom
pneumonia
bronchiol
acut
rhinosinus
influenzalik
ill
addit
rv
could
detect
asthma
exacerb
substanti
proport
copd
exacerb
asthma
estim
affect
million
peopl
worldwid
copd
affect
million
peopl
caus
million
death
much
enorm
morbid
mortal
healthcar
cost
associ
asthma
copd
relat
acut
exacerb
therefor
recognit
rv
major
caus
asthma
copd
exacerb
stimul
new
interest
biolog
treatment
part
research
investig
consid
whether
experiment
infect
studi
human
could
extend
healthi
volunt
patient
asthma
copd
respiratori
virus
detect
asthma
exacerb
children
exacerb
adult
rv
commonest
viru
detect
recognit
role
rv
asthma
exacerb
stimul
research
biolog
attempt
develop
treatment
virusinduc
exacerb
research
includ
investig
whether
experiment
rv
infect
could
use
peopl
asthma
way
use
healthi
individu
first
experiment
rv
challeng
subject
asthma
carri
dalhousi
univers
canada
volunt
inocul
becam
infect
decreas
forc
expiratori
volum
second
fev
increas
airway
hyperreact
ahr
author
felt
find
suggest
viral
pathogen
may
play
import
role
precipit
asthma
attack
unclear
studi
fail
induc
featur
asthma
exacerb
would
almost
anoth
decad
experiment
rv
infect
studi
peopl
asthma
attempt
experiment
infect
studi
allerg
nonasthmat
subject
suggest
rv
infect
could
induc
chang
lower
airway
physiolog
similar
seen
asthma
experiment
infect
studi
univers
southampton
unit
kingdom
includ
small
group
peopl
allerg
asthma
report
upper
respiratori
symptom
sever
atop
subject
report
lower
airway
symptom
physiolog
concurr
studi
use
pcr
detect
virus
natur
acquir
asthma
exacerb
strongli
support
role
rv
subsequ
studi
carri
research
group
unit
kingdom
netherland
unit
state
volunt
mild
intermitt
asthma
studi
demonstr
rv
infect
induc
airway
obstruct
increas
ahr
airway
inflamm
rv
could
detect
lower
airway
therebi
support
caus
role
rv
asthma
exacerb
establish
respiratori
virus
trigger
asthma
exacerb
research
focus
investig
rv
caus
benign
selflimit
ill
healthi
subject
result
sever
manifest
peopl
asthma
studi
natur
acquir
infect
cohabit
coupl
discord
asthma
suggest
peopl
asthma
suscept
viru
infect
lower
respiratori
tract
symptom
airway
inflamm
natur
acquir
infect
greater
peopl
asthma
compar
without
asthma
number
subject
studi
small
virus
detect
differ
two
group
viral
challeng
studi
ideal
suit
address
research
question
peopl
without
asthma
match
characterist
age
gender
infect
simultan
earlier
infect
studi
includ
control
group
healthi
volunt
therefor
could
address
question
whether
host
respons
infect
differ
peopl
asthma
studi
includ
nonasthmat
control
produc
somewhat
inconsist
result
one
studi
report
differ
lower
airway
inflammatori
cell
anoth
report
increas
nasal
inflammatori
mediat
asthma
discrep
result
regard
virusinduc
respiratori
symptom
diverg
result
like
relat
differ
sampl
method
time
antibodi
statu
subject
choic
healthi
control
eg
atop
vs
nonatop
first
studi
show
clear
differ
subject
without
asthma
respons
rv
infect
publish
studi
rv
challeng
induc
respiratori
symptom
greater
lung
function
impair
increas
bronchial
hyperreact
eosinophil
neutrophil
lower
airway
inflamm
asthmat
compar
normal
subject
direct
correl
loss
lung
function
degre
neutrophil
eosinophil
inflamm
nasal
viral
load
addit
studi
provid
insight
potenti
mechan
differenti
respons
viral
infect
peopl
asthma
despit
infect
dose
viru
postinocul
viru
load
tend
higher
asthmat
subject
compar
healthi
control
suggest
antivir
immun
may
impair
peopl
asthma
subsequ
failur
control
viral
replic
virolog
clinic
outcom
relat
defici
interferon
ifn
interleukin
il
respons
augment
thelper
type
h
respons
indic
excess
h
impair
h
immun
may
import
mechan
infect
rv
vitro
alveolar
macrophag
bronchial
epitheli
cell
subject
asthma
demonstr
defici
product
relat
sever
virusinduc
asthma
exacerb
report
subsequ
confirm
ifn
product
defici
asthma
find
replic
studi
may
phenomenon
occur
subset
peopl
asthma
seen
sever
poorli
control
asthma
patient
initi
includ
challeng
studi
limit
mild
wellcontrol
asthma
requir
inhal
corticosteroid
rv
challeng
shown
safe
small
group
peopl
wellcontrol
asthma
requir
longterm
use
inhal
corticosteroid
larger
studi
confirm
report
significantli
upper
lower
respiratori
symptom
greater
reduct
peak
expiratori
flow
fev
increas
viral
load
increas
bronchoalveolar
lavag
bal
eosinophil
increas
nasal
subject
moder
asthma
use
inhal
corticosteroid
studi
also
identifi
novel
mediat
virusinduc
asthma
exacerb
includ
poor
asthma
control
associ
sever
virusinduc
exacerb
greater
h
inflamm
higher
viru
load
therefor
respons
viru
infect
may
differ
depend
asthma
sever
control
may
account
discrep
result
earlier
experiment
infect
studi
success
viral
challeng
studi
pave
way
studi
subject
moder
asthma
reveal
new
insight
pathogenesi
exacerb
may
obtain
studi
mild
asthma
evid
emerg
research
includ
experiment
infect
studi
asthma
associ
defici
ifn
respons
led
develop
inhal
treatment
asthma
exacerb
clinic
trial
inhal
report
treatment
reduc
sever
virusinduc
exacerb
subgroup
patient
assess
sever
asthma
develop
inhal
ifn
novel
asthma
treatment
clear
demonstr
potenti
experiment
rv
infect
studi
contribut
discoveri
new
treatment
virusinduc
asthma
exacerb
global
initi
obstruct
lung
diseas
defin
copd
common
prevent
treatabl
diseas
character
persist
airflow
limit
usual
progress
associ
enhanc
chronic
inflammatori
respons
airway
lung
noxiou
particl
gase
exacerb
comorbid
contribut
overal
sever
individu
patient
acut
exacerb
copd
major
driver
morbid
mortal
healthcar
cost
copd
prevent
exacerb
major
unmet
need
acut
bacteri
infect
believ
main
caus
copd
exacerb
reflect
widespread
use
antibiot
copd
exacerb
although
copd
exacerb
preced
upper
respiratori
symptom
twothird
case
viru
detect
rate
prepcr
era
low
asthma
role
virus
copd
exacerb
reexamin
use
pcrbase
detect
method
although
detect
rate
respiratori
virus
copd
exacerb
variabl
asthma
respiratori
virus
detect
copd
exacerb
rv
predomin
viru
type
detect
despit
emerg
evid
implic
respiratori
virus
signific
proport
copd
exacerb
scientif
clinic
research
continu
focu
bacteri
infect
evid
almost
two
decad
first
experiment
rv
infect
studi
carri
asthma
similar
studi
copd
attempt
despit
excel
safeti
record
experiment
infect
studi
asthma
caution
warrant
repeat
studi
copd
major
differ
two
popul
copd
patient
older
current
exsmok
impair
lung
function
irrevers
airflow
obstruct
factor
potenti
result
sever
respons
experiment
rv
challeng
compar
younger
nonsmok
patient
rel
normal
baselin
lung
function
recruit
asthma
infect
studi
first
experiment
infect
studi
copd
small
pilot
studi
publish
establish
safeti
rv
infect
four
patient
moder
airflow
obstruct
fev
predict
use
regular
inhal
therapi
subject
develop
symptom
consist
copd
exacerb
follow
rv
inocul
togeth
object
marker
exacerb
fall
lung
function
increas
upper
airway
inflammatori
marker
subject
recov
complet
without
treatment
advers
event
report
subsequ
research
group
carri
two
larger
studi
experiment
rv
infect
subject
copd
noncopd
control
subject
studi
replic
find
pilot
studi
wherein
rv
infect
manifest
cold
symptom
lower
respiratori
symptom
consist
exacerb
copd
includ
airway
inflamm
worsen
airflow
obstruct
studi
provid
import
causal
evid
link
viru
infect
copd
exacerb
studi
natur
acquir
infect
support
link
provid
definit
evid
pcr
evalu
detect
viral
nucleic
acid
therefor
prove
presenc
live
viru
sampl
collect
exacerb
onset
respiratori
viru
nucleic
acid
also
detect
copd
patient
stabl
diseas
although
usual
elev
copd
exacerb
experiment
infect
model
rv
present
airway
sampl
prior
exacerb
onset
viru
load
increas
parallel
increas
symptom
airflow
obstruct
inflamm
clearanc
viru
associ
exacerb
resolut
strong
correl
observ
viru
load
airway
neutrophil
number
neutrophil
elastas
tumor
necrosi
factoralpha
granulocyt
macrophag
coloni
stimul
factor
also
correl
level
epigenet
regul
histon
deacetylas
inflammatori
respons
greater
patient
copd
studi
rv
infect
sole
experiment
agent
respons
increas
inflammatori
marker
patient
copd
provid
strong
evid
rv
infect
directli
caus
exacerb
copd
patient
anoth
advantag
viru
challeng
studi
natur
acquir
infect
abil
carri
detail
repeat
lower
airway
sampl
cours
exacerb
includ
use
bronchoscopi
provid
wealth
mechanist
data
regard
pathogenesi
virusinduc
exacerb
includ
presenc
inflammatori
mediat
inflammatori
cell
oxid
nitros
stress
impair
antivir
ifn
respons
novel
observ
emerg
studi
secondari
bacteri
infect
occur
experiment
virusinduc
exacerb
wherea
coinfect
rare
report
natur
acquir
exacerb
analysi
respiratori
microbiom
follow
experiment
rv
infect
suggest
secondari
infect
occur
due
outgrowth
previous
present
airway
bacteria
potenti
mechan
secondari
bacteri
infect
includ
reduc
antimicrobi
peptid
increas
glucos
airway
subsequ
studi
natur
acquir
exacerb
sampl
multipl
time
point
exacerb
confirm
valid
observ
therefor
although
number
copd
subject
recruit
viru
challeng
studi
date
small
rv
infect
appear
safe
popul
replic
featur
natur
acquir
infect
studi
includ
larger
number
patient
need
valid
find
investig
mechan
virusinduc
exacerb
copd
sinc
first
studi
healthi
volunt
experiment
rv
infect
extend
patient
asthma
copd
contribut
enorm
expand
understand
biolog
rv
infect
affect
patient
chronic
airway
diseas
summari
key
find
human
experiment
infect
studi
peopl
asthma
copd
provid
tabl
studi
tend
narrow
focu
rv
infect
host
immun
respons
clear
vivo
vitro
studi
interact
respiratori
viru
infect
factor
exacerb
asthma
copd
bacteria
allergen
air
pollut
factor
somewhat
neglect
viral
challeng
studi
promis
field
futur
research
start
address
mention
previous
use
viral
challeng
model
asthma
much
advanc
compar
copd
one
studi
identifi
ifndefici
copd
replic
develop
inhal
ifn
therapi
option
asthma
role
ifn
copd
requir
urgent
investig
area
futur
research
includ
effect
viru
infect
novel
pathway
lipidom
metabolom
asthma
copd
respiratori
virus
also
identifi
trigger
exacerb
airway
diseas
cystic
fibrosi
bronchiectasi
evid
impair
antivir
immun
diseas
experiment
infect
studi
may
help
defin
role
viru
infect
patient
popul
aa
expos
allergen
placebo
aa
expos
rv
aa
expos
rv
allergen
perhap
promis
use
viru
challeng
model
acceler
process
drug
develop
viru
challeng
studi
use
evalu
effect
exist
asthma
therapi
virusinduc
exacerb
recent
first
studi
use
viral
challeng
evalu
novel
unlicens
drug
asthma
also
publish
although
studi
neg
result
demonstr
potenti
viral
challeng
model
drug
develop
key
success
drug
develop
identif
clinic
relev
mechan
rv
infect
immunopatholog
experiment
manipul
therapeut
benefit
human
experiment
rv
infect
complement
work
anim
model
number
option
model
human
rv
infect
anim
model
provid
abil
investig
specif
diseas
compon
mechan
would
otherwis
imposs
human
human
experiment
infect
model
advantag
identifi
diseas
correl
degre
experiment
manipul
possibl
extrem
limit
safeti
effect
intervent
must
first
evalu
anim
anim
model
proven
use
mechanist
studi
across
rang
diseas
model
rv
infect
report
sever
anim
speci
includ
mous
cotton
rat
nonhuman
primat
experiment
system
provid
advantag
disadvantag
substanti
contribut
knowledg
base
biolog
rv
infect
anim
model
provid
rang
benefit
complement
human
experiment
approach
experiment
anim
readili
manipul
induc
consist
diseas
outcom
induct
allerg
airway
diseas
aad
model
asthma
cigarett
copd
anim
model
less
variabl
human
popul
provid
consist
experiment
outcom
statist
power
intervent
studi
experiment
environ
exposur
eg
previou
infect
histori
endpoint
interindividu
variabl
control
broad
array
tool
avail
character
diseas
outcom
includ
reagent
genet
modifi
anim
strain
experiment
protocol
assess
techniqu
eg
lung
function
test
sampl
tissu
easili
isol
experiment
endpoint
difficult
imposs
sampl
human
eg
lung
tissu
drain
lymph
node
bone
marrow
anim
model
serv
valuabl
preclin
system
assess
novel
intervent
provid
proofofprincipl
safeti
efficaci
find
prior
exposur
healthi
human
volunt
mice
particular
extens
use
model
diseas
includ
viru
infect
exacerb
asthma
copd
result
wealth
tool
techniqu
avail
studi
immun
mechan
pathophysiolog
mice
wellcharacter
protocol
reagent
support
induct
diseas
state
allow
detail
character
immun
respons
eg
fluoresc
tag
monoclon
antibodi
quantifi
immun
cell
subset
rang
transgen
knockout
mous
strain
avail
allow
care
dissect
relev
diseas
mechan
reagent
avail
assess
effect
novel
intervent
diseas
outcom
eg
block
antibodi
variou
form
innat
immun
activ
see
chapter
emerg
therapeut
approach
expans
mous
rv
infect
model
parallel
understand
rv
biolog
human
initi
approach
focus
understand
effect
rv
infect
isol
identifi
mechan
cell
type
mediat
lung
patholog
increasingli
complex
experiment
model
use
character
longterm
effect
infect
airway
function
effect
rv
infect
preexist
airway
diseas
eg
asthma
exacerb
one
biggest
develop
mous
rv
infect
model
protocol
isol
highli
purifi
concentr
high
titer
rv
henrietta
lack
hela
immort
human
epitheli
cell
line
later
intracellular
adhes
molecul
transfect
rhabdomyosarcoma
cell
line
prior
clarifi
infect
hela
cell
lysat
use
vitro
experi
investig
also
use
infect
hela
cell
lysat
mous
model
effort
improv
qualiti
valid
model
made
use
partial
purif
protocol
gener
viral
stock
mous
model
rv
infect
exacerb
refin
hightit
rv
purif
protocol
gold
standard
major
barrier
hinder
earli
develop
mous
model
speci
specif
rv
infect
majorgroup
rv
strain
make
approxim
rv
strain
enter
cell
bind
rv
bind
limit
human
chimpanze
occur
speci
includ
mous
result
majorgroup
rv
strain
infect
mous
cell
fail
replic
induc
patholog
mous
model
earli
attempt
develop
rv
mous
model
fail
detect
suffici
viral
replic
induc
diseas
major
advanc
enabl
develop
mous
rv
infect
model
initi
recognit
minorgroup
use
host
cell
receptor
lowdens
lipoprotein
receptor
infect
mous
epitheli
cell
line
recognit
suggest
minorgroup
rv
virus
eg
may
use
model
infect
mice
vivo
inde
inocul
wildtyp
balbc
mice
induc
lung
patholog
mucu
product
inflammatori
cytokin
product
notabl
rv
infect
also
suffici
induc
exacerb
preexist
asthma
sensit
challeng
mice
discuss
detail
altern
approach
also
sought
allow
model
majorgroup
rv
infect
mice
studi
tuthil
et
al
demonstr
transfect
cell
chimer
receptor
contain
human
extracellular
receptor
domain
allow
infect
replic
majorgroup
viru
find
provid
basi
develop
transgen
mous
strain
express
chimer
receptor
chimer
receptor
express
huicam
tg
mice
suffici
support
vivo
infect
result
airway
inflamm
mucu
product
viral
replic
inflammatori
cytokin
product
note
huicam
tg
mous
gener
random
insert
chimer
transgen
littl
known
transgen
insert
site
within
genom
use
transgen
strain
requir
addit
experiment
consider
eg
genotyp
use
heterozyg
anim
experi
limit
broad
util
addit
variat
also
report
literatur
aim
broaden
avail
mous
model
genet
variant
gener
serial
passag
mous
embryon
fibroblast
vitro
lung
epitheli
cell
vivo
exhibit
increas
growth
mous
cell
inocul
balbc
mice
variant
plaqu
form
unit
pfu
allow
recoveri
viru
mous
lung
hour
mice
also
pretreat
intranas
hydrochlor
acid
increas
epitheli
permeabl
success
use
mous
model
also
depend
develop
streamlin
rv
isol
protocol
allow
consist
rapid
isol
viru
stock
limit
variabl
experi
current
goldstandard
protocol
rv
isol
infect
wildtyp
balbc
mice
infect
transgen
mice
express
chimer
receptor
publish
readili
avail
rang
studi
assess
effect
primari
rv
infect
mice
contribut
understand
mechan
underli
diseas
pathogenesi
studi
use
similar
protocol
typic
perform
intranas
inocul
tcid
tissu
cultur
infect
dose
cultur
titrat
infect
unit
pathogen
form
plaqu
cultur
assess
respons
week
follow
infect
balbc
mice
initi
public
bartlett
et
al
intranas
inocul
wildtyp
balbc
mice
tcid
induc
rang
diseas
featur
similar
human
diseas
rv
infect
induc
airway
inflamm
character
increas
neutrophil
number
hour
postinfect
increas
lymphocyt
number
persist
postinfect
tissu
patholog
character
perivascular
peribronchi
inflamm
increas
mucu
product
elev
inflammatori
cytokin
product
includ
kc
rant
itac
furthermor
rv
infect
result
develop
rvspecif
adapt
antibodi
respons
day
postinfect
studi
provid
insight
effect
rv
infect
alon
mice
follow
inocul
wildtyp
mice
tcid
detect
rv
positiveand
negativestrand
rna
recov
lung
indic
activ
viral
replic
viral
rna
detect
day
postinfect
studi
also
notic
small
increas
airway
neutrophil
lymphocyt
presenc
uvinactiv
although
uvinactiv
majorgroup
viru
fail
induc
inflammatori
cytokin
product
infect
also
increas
airway
respons
methacholin
challeng
day
postinfect
inocul
uvinactiv
induc
activ
airway
epitheli
cell
pretreat
inhibitor
vivo
dampen
neutrophil
inflamm
inflammatori
cytokin
product
kc
inocul
mice
tcid
lead
discontinu
express
zonula
suggest
infect
disrupt
airway
epitheli
barrier
function
rv
infect
also
stimul
product
releas
airway
depend
type
ifn
product
stimul
activ
natur
killer
nk
cell
respons
treatment
complex
increas
express
stimul
increas
nk
cell
recruit
activ
upregul
lung
transcript
follow
infect
block
function
reduc
lung
neutrophil
macrophag
accumul
ifn
respons
block
also
reduc
ahr
public
also
delin
ahr
inflammatori
infiltr
show
instead
relationship
classic
proinflammatori
transcript
factor
ahr
allud
previous
use
knockout
mice
particular
provid
insight
number
mechan
regul
rvinduc
patholog
key
role
neutrophil
neutrophil
chemokin
receptor
mediat
rvinduc
patholog
identifi
inocul
mice
tcid
result
reduc
airway
neutrophil
number
reduc
inflammatori
cytokin
product
kc
decreas
mucu
product
decreas
cholinerg
respons
alter
viral
load
compar
wildtyp
control
anim
antibodi
deplet
neutrophil
infect
tnfr
mice
also
reduc
ahr
compar
control
anim
find
provid
evid
role
neutrophil
inflamm
potenti
via
product
downstream
patholog
follow
rv
infect
role
pattern
recognit
molecul
demonstr
tolllik
receptor
infect
mice
result
delay
type
ifn
suppress
type
iii
ifn
express
slight
earli
increas
viral
load
lung
contrast
inocul
mice
result
normal
ifn
respons
differ
viral
yield
mice
reduc
neutrophil
number
inflammatori
cytokin
product
airway
respons
compar
wildtyp
control
differ
role
signal
pathway
rvinduc
inflamm
type
inf
respons
antivir
immun
demonstr
disrupt
signal
mice
result
reduc
neutrophil
number
inflammatori
cytokin
product
ifn
product
viral
load
unalt
contrast
mice
unalt
neutrophil
inflamm
persist
increas
lymphocyt
number
cytokin
reduc
product
increas
viral
load
pathogen
role
proinflammatori
molecul
also
demonstr
increas
express
antivir
gene
reduc
neutrophil
inflamm
viral
load
mice
follow
inocul
pfu
studi
use
tbet
mice
key
regul
h
cell
differenti
also
demonstr
key
role
h
cell
respons
rv
infect
tbet
mice
develop
h
h
immun
respons
rv
infect
tcid
increas
product
defici
nk
cell
respons
decreas
neutral
antibodi
develop
cell
contribut
increas
airway
eosinophil
number
mucu
product
follow
rv
infect
tbet
mice
studi
use
tslp
receptordefici
mice
tslpr
demonstr
infect
interfer
toler
inhal
allergen
via
mechan
requir
tslp
activ
lung
dendrit
cell
observ
increas
level
tnf
super
famili
member
protein
trail
product
time
cours
infect
mice
girkin
et
al
compar
infect
mice
wildtyp
balbc
mice
observ
almost
complet
ablat
inflammatori
respons
follow
rv
infect
peribronchiolar
inflamm
lung
histopatholog
reduc
mice
neutrophil
lymphocyt
bal
remain
baselin
cell
cell
nk
plasmacytoid
dendrit
cell
pdc
myeloid
dendrit
cell
reduc
flow
cytometri
total
lung
cell
mice
protect
rvinduc
ahr
fail
develop
rvinduc
exacerb
allerg
airway
diseas
interest
provir
effect
trail
also
identifi
wherebi
mice
reduc
viral
load
antitrail
antibodi
reduc
viral
load
wherea
recombin
trail
administr
increas
viral
load
cell
infect
vitro
effect
viral
load
independ
ifn
respons
may
associ
unidentifi
role
apoptosi
rv
replic
remain
explor
studi
assess
effect
primari
rv
infect
clinic
relev
sequela
includ
secondari
bacteri
infect
effect
prematur
birth
infect
exposur
epitheli
cell
cultur
result
increas
bacteri
attach
transloc
epitheli
monolay
nontyp
haemophilu
influenza
nthi
pseudomona
aeruginosa
staphylococcu
aureu
suggest
potenti
mechan
underli
secondari
bacteri
infect
follow
viral
infect
subsequ
studi
demonstr
primari
inocul
tcid
delay
clearanc
nthi
vivo
associ
suppress
chemokin
product
kc
neutrophil
inflamm
mechan
model
also
use
assess
immun
alter
relev
prematur
birth
bronchopulmonari
dysplasia
risk
factor
viralinduc
exacerb
exposur
neonat
mice
hyperoxia
oxygen
earli
life
increas
inflammatori
cytokin
express
suppress
earli
ifn
respons
follow
infect
pfu
day
age
one
studi
also
assess
effect
rv
infect
time
subsequ
develop
aad
inocul
mice
subsequ
induct
hous
dust
mite
hdm
induc
allerg
airway
diseas
addit
effect
increas
neutrophilia
ahr
femal
mice
although
rv
inocul
addit
impact
male
mice
studi
extend
use
rv
infect
mice
new
area
includ
mechan
earli
life
infect
suscept
mechan
secondari
bacteri
infectioncompromis
antimicrobi
immun
experiment
explor
clinic
risk
factor
associ
increas
likelihood
develop
virusinduc
exacerb
respiratori
diseas
mous
model
valuabl
tool
preclin
test
novel
treatment
sever
studi
use
mous
rv
infect
model
assess
intervent
strategi
includ
vaccin
develop
drug
treatment
primari
inocul
balbc
tcid
rapidli
induc
circul
rvspecif
igg
antibodi
product
within
day
bind
capsid
protein
antibodi
crossreact
anoth
minor
strain
rv
repeat
rv
infect
necessari
induc
rvspecif
iga
respons
neutral
antibodi
administr
cpg
subcutan
immun
freund
adjuv
promot
neutral
antibodi
develop
may
inform
potenti
vaccin
strategi
pretreat
plant
flavanol
quercetin
infect
effect
reduc
viral
replic
inflammatori
cytokin
product
kc
ahr
treatment
cancer
therapeut
gemcitabin
reduc
rv
load
inflammatori
cytokin
level
reduc
lung
lymphocyt
number
treatment
corticosteroid
therapi
fluticason
proprion
suppress
ifn
respons
rv
reduc
airway
inflamm
lead
increas
mucu
product
reduc
antimicrobi
respons
effect
viral
load
mucin
product
antibacteri
respons
could
revers
administr
recombin
despit
promis
find
mous
model
quercetin
enter
clinic
trial
treatment
rv
infect
like
due
previou
random
commun
clinic
trial
show
littl
benefit
quercetin
supplement
upper
respiratori
infect
find
may
highlight
limit
mous
model
valuabl
alway
fulli
recapitul
human
diseas
mechan
anim
model
studi
rvmediat
exacerb
airway
diseas
also
develop
model
combin
experiment
rv
infect
model
airway
diseas
includ
asthma
copd
chronic
rhinosinus
model
asthma
typic
consist
administr
sensit
agent
eg
ovalbumin
ova
hdm
subsequ
challeng
airway
induc
eosinophil
allerg
airway
diseas
copd
typic
induc
prolong
repeat
exposur
mice
cigarett
smoke
treatment
elastas
airway
diseas
establish
mice
inocul
rv
induc
diseas
exacerb
model
explain
expand
upon
follow
section
research
also
use
doublestrand
rna
dsrna
administr
surrog
viru
infect
exacerb
preexist
diseas
review
ref
howev
approach
fail
model
complex
viru
infect
beyond
scope
current
book
chapter
mani
studi
character
effect
rv
infect
preexist
asthma
provid
insight
immun
cell
type
involv
key
molecul
respons
potenti
therapi
initi
report
rv
exacerb
model
ovasensit
challeng
balbc
mice
inocul
allergen
challeng
phase
combin
viru
allergen
challeng
increas
airway
neutrophil
eosinophil
lymphocyt
number
increas
cytokin
product
increas
ahr
increas
mucu
gene
express
subsequ
studi
identifi
key
function
role
macrophag
gammadelta
cell
dendrit
cell
subset
neutrophil
rvinduc
immunopatholog
similar
model
inocul
ovasensitizedchalleng
mice
increas
macrophag
lung
infiltr
express
eotaxin
express
pulmonari
macrophag
lung
combin
viru
infect
allergen
challeng
macrophag
deplet
antieotaxin
treatment
reduc
rvinduc
airway
eosinophilia
ahr
macrophag
activ
state
also
modul
respons
rv
infect
allergen
sensitizedchalleng
mice
shape
result
pattern
inflamm
rv
infect
asthma
exacerb
model
induc
macrophag
popul
polar
phenotyp
deplet
cell
mice
mice
reduc
airway
inflamm
ahr
interestingli
rv
infect
ovatr
wildtyp
mice
contribut
mix
neutrophil
eosinophil
airway
inflamm
macrophag
phenotyp
mice
exhibit
neutrophil
inflamm
alon
increas
polar
pulmonari
macrophag
still
exacerb
airway
respons
cell
dampen
exacerb
respons
cell
increas
rvinduc
asthma
exacerb
model
block
respons
antibodi
worsen
exacerb
increas
ahr
increas
number
h
cell
eosinophil
effect
viru
load
pdc
recruit
lung
rvinduc
inflamm
subsequ
promot
h
respons
lung
drain
lymph
node
process
mediat
deplet
pdc
antibodi
treatment
reduc
eosinophil
number
decreas
lung
patholog
reduc
cytokin
product
reduc
ahr
function
role
neutrophil
neutrophil
extracellular
trap
net
also
provid
rvinduc
asthma
exacerb
model
chronic
lowdos
hdm
exposur
rv
infect
addit
effect
neutrophilia
induc
ahr
recent
studi
demonstr
rv
infect
hdmmediat
asthma
model
result
doublestrand
dna
releas
airway
administr
genom
dna
alon
suffici
mimic
characterist
compon
rvinduc
exacerb
block
neutrophil
elastas
degrad
net
appli
dnase
airway
reduc
eosinophil
lymphocyt
number
tissu
patholog
cytokin
product
number
studi
highlight
function
role
specif
molecul
rvinduc
mous
exacerb
model
potenti
therapeut
target
valid
patient
popul
addit
role
rv
infect
alon
highlight
also
involv
rvinduc
exacerb
mice
decreas
inflammatori
respons
ahr
also
decreas
ifn
respons
midlin
ubiquitin
ligas
upregul
hdminduc
model
short
interf
inhibit
prior
rv
inocul
reduc
neutrophil
number
mucu
product
product
monocyt
chemotact
protein
produc
epitheli
cell
macrophag
follow
rvinduc
exacerb
administr
antibodi
reduc
eosinophil
number
ahr
transgen
mice
produc
excess
mucu
airway
rv
infect
increas
express
mice
rv
clearanc
increas
increas
activ
express
also
increas
rvinduc
exacerb
block
receptor
reduc
type
cytokin
product
tslp
mucu
product
number
eosinophil
neutrophil
cell
innat
lymphoid
type
cell
combin
dsrna
administr
inocul
worsen
preexist
allerg
airway
diseas
repeat
dsrna
administr
ova
sensit
challeng
result
neutrophil
lung
inflamm
tissu
patholog
combin
dsrna
inocul
increas
express
tslp
lung
key
role
pattern
recognit
receptor
also
demonstr
rv
asthma
exacerb
model
hdmallerg
mice
decreas
antivir
respons
reduc
ifn
releas
increas
viru
replic
associ
increas
eosinophil
lymphocyt
number
increas
ahr
administr
ifn
transfer
wildtyp
pdc
could
restor
antivir
respons
reduc
diseas
exacerb
ovaallerg
mice
also
reduc
macrophag
neutrophil
eosinophil
number
suppress
ahr
rv
inocul
bone
marrow
transfer
experi
demonstr
bone
marrow
could
protect
exacerb
transfer
wildtyp
bone
marrow
restor
respons
mice
transfer
wildtyp
macrophag
mice
could
also
restor
exacerb
previous
mention
role
trail
also
demonstr
hdmallerg
traildefici
mice
protect
rvinduc
ahr
induct
airway
inflamm
rvinduc
asthma
exacerb
model
also
use
assess
respons
exist
therapi
preclin
model
novel
therapi
treatment
hdmallerg
mice
long
act
agonist
salmeterol
reduc
ahr
eosinophil
number
rv
exacerb
limit
chemokin
level
modul
find
studi
focus
novel
therapeut
target
rather
promot
salmeterol
monotherapi
associ
advers
event
toler
chronic
salmeterol
use
approach
block
majorgroup
rv
viru
infect
assess
administr
antihuman
antibodi
prevent
entri
reduc
neutrophil
lymphocyt
number
cytokin
product
mucu
product
viru
load
human
transgen
mice
ovaallerg
model
treatment
nontox
anthraquinon
deriv
reduc
rvinduc
ahr
neutrophil
eosinophil
airway
inflamm
inflammatori
cytokin
product
mucu
hypersecret
also
boost
type
ifn
respons
reduc
viral
yield
associ
decreas
akt
vegf
product
treatment
antiinflammatori
inhibitor
macrolid
antibiot
azithromycin
also
reduc
neutrophil
number
reduc
ahr
follow
inocul
hdmallerg
mice
mous
chronic
obstruct
pulmonari
diseas
exacerb
model
rv
also
play
import
role
virusinduc
exacerb
copd
sever
studi
assess
effect
rv
inocul
anim
model
copd
exposur
elastas
lipopolysaccharid
lp
per
week
week
induc
featur
copd
includ
airway
inflamm
goblet
cell
metaplasia
alter
lung
function
addit
led
persist
viral
rna
day
postinfect
defici
ifn
respons
increas
ahr
lung
volum
cytokin
product
mucu
product
compar
elastaselp
administr
alon
subsequ
studi
attempt
replic
elastaselp
model
copd
found
singl
elastas
treatment
follow
inocul
enough
increas
airway
neutrophil
lymphocyt
number
increas
inflammatori
cytokin
product
mucu
hypersecret
ahr
elastaseinduc
model
fluticason
proprion
treatment
reduc
ifn
respons
increas
viral
load
suppress
airway
immun
cell
number
lymphocyt
neutrophil
suppress
inflammatori
cytokin
increas
mucu
product
follow
exacerb
differ
experiment
approach
requir
elicit
rvinduc
exacerb
differ
studi
like
due
qualiti
viru
inoculum
use
differ
investig
explain
previous
influenc
purif
approach
first
studi
use
crude
virusinfect
cell
lysat
wherea
later
studi
employ
highli
purifi
viru
inoculum
sever
studi
also
report
rv
infect
cigarett
copd
model
initi
studi
week
cigarett
smoke
exposur
result
increas
viral
persist
neutrophilia
increas
mucu
product
follow
rv
infect
subsequ
studi
demonstr
goblet
cell
gene
express
reduc
follow
treatment
gammasecretas
inhibitor
gsk
limit
notch
activ
supplement
feed
quercetin
reduc
rvinduc
lung
inflamm
includ
neutrophilia
goblet
cell
metaplasia
ahr
knowledg
one
studi
assess
effect
rv
infect
chronic
sinus
model
mous
model
chronic
allerg
rhinosinus
induc
week
repetit
nasal
ova
challeng
increas
yield
report
nasal
tissu
mice
rhinosinus
although
inflammatori
cytokin
product
histopatholog
unaffect
studi
serv
illustr
rang
addit
diseas
rv
infect
shown
relev
human
popul
anim
model
avail
futur
research
eg
cystic
fibrosi
limit
number
studi
report
use
rv
infect
anim
name
cotton
rat
nonhuman
primat
note
histor
studi
assess
rv
infect
anim
speci
refer
genet
distinct
viral
genera
confus
human
rv
eg
equin
rv
bovin
rv
exampl
human
rv
equin
rv
origin
assign
rhinoviru
genu
reclassifi
enteroviru
apthoviru
respect
equin
rv
subsequ
renam
equin
rhiniti
viru
cotton
rat
sigmodon
hispidu
recogn
model
human
respiratori
infect
particularli
respiratori
syncyti
viru
well
adenovirus
parainfluenza
viru
measl
human
metapneumoviru
review
ref
date
two
studi
report
rv
infect
cotton
rat
provid
evid
cotton
rat
partial
permiss
rv
majorgroup
infect
intranas
inocul
pfu
cotton
rat
induc
lower
respiratori
histopatholog
increas
mucu
product
induct
infactiv
gene
immun
live
high
level
circul
antibodi
protect
subsequ
infect
prophylact
transfer
serum
also
protect
diseas
protect
transfer
effect
mother
newborn
limit
viral
yield
subsequ
infect
progeni
later
studi
group
provid
evid
infect
pfu
induc
similar
diseas
patholog
furthermor
immun
provid
protect
subsequ
infect
either
rvb
group
viru
rva
group
viru
demonstr
degre
crossreact
differ
majorgroup
virus
chimpanze
gibbon
nonhuman
primat
support
rv
infect
although
rv
infect
also
report
vervet
monkey
cell
consist
infect
requir
high
dose
exposur
initi
rv
infect
studi
chimpanze
report
use
gibbon
subsequ
studi
chimpanze
gibbon
assess
antivir
effect
drug
treatment
rv
infect
use
bisbenzimidazol
triazinoindol
respect
administr
solubl
truncat
form
human
prevent
subsequ
infect
chimpanze
howev
note
neither
chimpanze
gibbon
develop
cold
symptom
follow
rv
infect
high
cost
logist
studi
limit
progress
chimpanze
endang
speci
requir
consider
resourc
facil
research
current
chimpanze
research
limit
unit
state
gabon
howev
nation
institut
health
unit
state
indic
seek
elimin
use
chimpanze
research
one
speci
gibbon
endang
thu
clinic
research
use
nonhuman
primat
futur
character
rv
infect
like
limit
nonexist
rv
normal
infect
rodent
attenu
mengoviru
infect
model
propos
altern
option
model
rv
infect
mengoviru
also
belong
picornavirida
famili
normal
caus
system
infect
rodent
use
attenu
mengoviru
intranas
inocul
pfu
rat
increas
airway
neutrophil
lymphocyt
number
induc
lung
tissu
patholog
increas
express
subsequ
report
use
genet
attenu
mengoviru
vmc
mice
also
induc
lower
respiratori
tract
infect
increas
lung
neutrophil
lymphocyt
number
express
inf
chemokin
respiratori
viru
infect
associ
acut
exacerb
asthma
copd
includ
respiratori
syncyti
viru
influenza
human
coronaviru
human
parainfluenza
viru
human
metapneumovirus
adenovirus
anim
model
infect
larg
limit
specif
virus
human
unclear
extent
mechan
caus
patholog
differ
differ
virus
strain
viru
detail
discuss
diseas
process
induc
differ
viru
infect
beyond
scope
chapter
detail
analysi
relev
diseas
mechan
infect
set
necessari
inform
understand
diseas
exacerb
ideal
identifi
common
mechan
virus
target
therapi
anim
model
complet
recapitul
natur
occur
human
rv
infect
anim
model
provid
import
insight
diseas
mechan
import
also
recogn
limit
recogn
limit
mice
model
human
respiratori
diseas
includ
differ
responsesymptom
speci
human
differ
respiratori
tract
architectur
human
nonhuman
primat
mous
airway
rang
dichotoma
airway
split
two
trichotoma
airway
split
three
monopodi
branch
central
airway
continu
subordin
airway
branch
differ
airflow
inhomogen
cover
detail
miller
et
al
also
differ
mucu
product
process
mous
compar
human
airway
short
lifespan
laboratori
anim
captur
lifecours
human
diseas
mice
natur
develop
asthma
copd
current
model
asthma
repres
eosinophil
allerg
pattern
diseas
remain
unclear
extent
current
model
pathophysiolog
truli
reflect
human
diseas
particularli
consid
recogn
heterogen
human
popul
rv
evolv
effici
replic
human
respiratori
tract
due
decreas
effici
rv
entri
nonhuman
epitheli
cell
like
differ
nuanc
cellular
machineri
requir
replic
high
amount
viral
load
requir
elicit
biolog
respons
rv
laboratori
anim
eg
tcid
mous
vs
tcid
experiment
human
infect
model
human
rv
strain
also
demonstr
limit
viral
replic
differ
replic
kinet
mous
man
differ
highlight
import
confirm
find
relev
patient
cohortssampl
util
use
human
experiment
model
parallel
anim
model
point
pure
academ
consider
import
take
consider
clinic
trial
design
outcom
exampl
mous
model
highlight
key
relev
asthma
patholog
use
knockout
mice
antibodi
blockad
howev
initi
random
control
trial
assess
therapi
mepolizumab
broad
asthma
popul
fail
demonstr
clinic
effect
subsequ
trial
limit
recruit
patient
demonstr
eosinophil
asthma
patient
subset
close
model
experiment
mous
system
clinic
improv
observ
futur
direct
anim
model
similar
way
experiment
human
infect
model
narrow
focu
anim
model
mice
focu
larg
rv
infect
alon
grow
bodi
literatur
assess
asthma
exacerb
difficult
model
mice
rvinduc
copd
exacerb
model
emerg
use
elastas
administr
cigarett
copd
summari
key
find
mous
model
rvinduc
exacerb
airway
diseas
present
tabl
limit
studi
report
rv
effect
potenti
intervent
model
human
experiment
infect
anim
infect
model
may
also
relev
expand
array
diseas
futur
eg
cf
bronchiectasi
date
limit
assess
across
differ
rv
strain
anim
human
studi
primari
focu
rv
model
mice
human
possibl
due
avail
strain
eas
grow
strain
cell
cultur
particular
due
rel
recent
discoveri
rvc
infect
yet
assess
anim
model
far
difficulti
gener
suffici
quantiti
rvc
research
purpos
particularli
infecti
titer
requir
mous
model
recent
establish
suitabl
cell
line
hela
cell
support
rvc
replic
gap
literatur
like
rectifi
elastaselp
nil
defici
antivir
immun
increas
inflamm
exagger
ahr
increas
mucin
express
case
major
human
infect
model
mous
semipermiss
rv
infect
hightit
inoculum
requir
induc
prolong
replic
robust
reproduc
host
immun
respons
mouseadapt
rv
strain
gener
serial
passag
mous
epitheli
cell
cell
though
mouseadapt
viru
character
vitro
primari
mous
tracheal
epitheli
cell
yet
test
vivo
clinic
translat
novel
therapi
identifi
anim
model
treatment
rv
infect
human
yet
come
fruition
howev
multipl
molecul
current
drug
develop
pipelin
rang
virustarget
molecul
drug
target
host
factor
viral
replic
cycl
biolog
innat
immun
stimul
cytokin
block
monoclon
antibodi
elabor
chapter
emerg
therapeut
approach
signific
opportun
research
human
nonhuman
model
includ
assess
infect
variou
unexplor
diseas
background
exacerb
rv
infect
eg
cystic
fibrosi
expans
studi
use
newli
identifi
rv
strain
eg
rvc
strain
human
mous
rv
experiment
infect
model
effect
complement
contribut
immens
understand
mechan
shape
rvinduc
patholog
human
experiment
rv
challeng
studi
shed
light
biolog
rv
infect
mechan
associ
rvinduc
exacerb
chronic
respiratori
diseas
mous
model
rv
infect
particular
readili
manipulat
identifi
caus
effect
specif
molecul
diseas
outcom
preclin
test
excel
exampl
human
mous
model
complement
grow
understand
diseas
mechan
rvinduc
asthma
exacerb
human
experiment
infect
reveal
potenti
role
induc
type
immun
follow
rv
infect
individu
asthma
subsequ
mous
model
studi
demonstr
causal
role
rvinduc
type
immun
effector
molecul
exacerb
allow
preclin
assess
efficaci
safeti
novel
therapi
find
studi
yet
result
develop
approv
therapi
rv
infect
cold
symptom
exacerb
respiratori
diseas
associ
rv
infect
howev
wealth
knowledg
deriv
experiment
rv
infect
broaden
understand
identifi
mani
potenti
therapeut
approach
